463 related articles for article (PubMed ID: 22967121)
1. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori.
Chuah SK; Hsu PI; Chang KC; Chiu YC; Wu KL; Chou YP; Hu ML; Tai WC; Chiu KW; Chiou SS; Wu DC; Hu TH
Helicobacter; 2012 Jun; 17(3):216-23. PubMed ID: 22515360
[TBL] [Abstract][Full Text] [Related]
3. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China.
Qian J; Ye F; Zhang J; Yang YM; Tu HM; Jiang Q; Shang L; Pan XL; Shi RH; Zhang GX
Helicobacter; 2012 Dec; 17(6):478-85. PubMed ID: 23067317
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori.
Hu TH; Chuah SK; Hsu PI; Wu DC; Tai WC; Chiu YC; Wu KL; Kuo CM; Hu ML
Am J Med Sci; 2011 Sep; 342(3):177-81. PubMed ID: 21804375
[TBL] [Abstract][Full Text] [Related]
5. Levofloxacin versus clarithromycin in a 10 day triple therapy regimen for first-line Helicobacter pylori eradication: a single-blind randomized clinical trial.
Cuadrado-Lavín A; Salcines-Caviedes JR; Carrascosa MF; Dierssen-Sotos T; Cobo M; Campos MR; Ayestarán B; Fernández-Pousa A; González-Colominas E; Aresti-Zárate S; Hernández M; Pascual EL
J Antimicrob Chemother; 2012 Sep; 67(9):2254-9. PubMed ID: 22687889
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial.
Kuo CH; Hsu PI; Kuo FC; Wang SS; Hu HM; Liu CJ; Chuah SK; Chen YH; Hsieh MC; Wu DC; Tseng HH
J Antimicrob Chemother; 2013 Jan; 68(1):222-8. PubMed ID: 22984204
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection.
Federico A; Nardone G; Gravina AG; Iovene MR; Miranda A; Compare D; Pilloni PA; Rocco A; Ricciardiello L; Marmo R; Loguercio C; Romano M
Gastroenterology; 2012 Jul; 143(1):55-61.e1; quize e13-4. PubMed ID: 22484118
[TBL] [Abstract][Full Text] [Related]
8. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication.
Di Caro S; Franceschi F; Mariani A; Thompson F; Raimondo D; Masci E; Testoni A; La Rocca E; Gasbarrini A
Dig Liver Dis; 2009 Jul; 41(7):480-5. PubMed ID: 18974025
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
Kuo CH; Hu HM; Kuo FC; Hsu PI; Chen A; Yu FJ; Tsai PY; Wu IC; Wang SW; Li CJ; Weng BC; Chang LL; Jan CM; Wang WM; Wu DC
J Antimicrob Chemother; 2009 May; 63(5):1017-24. PubMed ID: 19246508
[TBL] [Abstract][Full Text] [Related]
10. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of a third-line, levofloxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection.
Tursi A; Picchio M; Elisei W
J Gastrointestin Liver Dis; 2012 Jun; 21(2):133-8. PubMed ID: 22720300
[TBL] [Abstract][Full Text] [Related]
12. Comparison of levofloxacin-containing sequential and standard triple therapies for the eradication of Helicobacter pylori.
Polat Z; Kadayifci A; Kantarcioglu M; Ozcan A; Emer O; Uygun A
Eur J Intern Med; 2012 Mar; 23(2):165-8. PubMed ID: 22284248
[TBL] [Abstract][Full Text] [Related]
13. Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice.
Zullo A; De Francesco V; Manes G; Scaccianoce G; Cristofari F; Hassan C
J Gastrointestin Liver Dis; 2010 Jun; 19(2):131-4. PubMed ID: 20593044
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of two levofloxacin-containing second-line therapies for Helicobacter pylori: a pilot study.
Calhan T; Kahraman R; Sahin A; Senates E; Doganay HL; Kanat E; Ozdil K; Sokmen HM
Helicobacter; 2013 Oct; 18(5):378-83. PubMed ID: 23601026
[TBL] [Abstract][Full Text] [Related]
16. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole.
Marzio L; Coraggio D; Capodicasa S; Grossi L; Cappello G
Helicobacter; 2006 Aug; 11(4):237-42. PubMed ID: 16882326
[TBL] [Abstract][Full Text] [Related]
17. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
Wong WM; Gu Q; Chu KM; Yee YK; Fung FM; Tong TS; Chan AO; Lai KC; Chan CK; Wong BC
Aliment Pharmacol Ther; 2006 Feb; 23(3):421-7. PubMed ID: 16423001
[TBL] [Abstract][Full Text] [Related]
18. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.
Antos D; Schneider-Brachert W; Bästlein E; Hänel C; Haferland C; Buchner M; Meier E; Trump F; Stolte M; Lehn N; Bayerdörffer E
Helicobacter; 2006 Feb; 11(1):39-45. PubMed ID: 16423088
[TBL] [Abstract][Full Text] [Related]
19. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
Hsu PI; Chen WC; Tsay FW; Shih CA; Kao SS; Wang HM; Yu HC; Lai KH; Tseng HH; Peng NJ; Chen A; Kuo CH; Wu DC;
Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study.
Assem M; El Azab G; Rasheed MA; Abdelfatah M; Shastery M
Eur J Intern Med; 2010 Aug; 21(4):310-4. PubMed ID: 20603042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
